
    
      The study period per participant was approximatively 44 weeks broken down as follows:

        -  Screening period up to 4 weeks,

        -  24-week double-blind treatment period*,

        -  16-week post-treatment elimination follow-up period.

      '*' participants successfully completing the week 24 visit were offered the opportunity to
      enter the optional long-term extension study LTS6047 - NCT00811395.
    
  